Does vaginal estriol make urodynamic changes in women with overactive bladder syndrome and genitourinary syndrome of menopause

Menopause

Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health

Menopause.

Faubion SS, Larkin LC, Stuenkel CA, Bachmann GA, Chism LA, Kagan R, Kaunitz AM, Krychman ML, Parish SJ, Partridge AH, Pinkerton JV, Rowen TS, Shapiro M, Simon JA, Goldfarb SB, Kingsberg SA

doi: 10.1097/GME.

Erectile and Sexual Functions and DysfunctionsMenopause

The impact of genitourinary syndrome of menopause on well-being, functioning, and quality of life in postmenopausal women

Menopause.

Moral E, Delgado JL, Carmona F, Caballero B, Guillán C, González PM, Suárez-Almarza J, Velasco-Ortega S, Nieto Magro C; writing group of GENISSE study

doi: 10.1097/GME.

Erectile and Sexual Functions and DysfunctionsMenopause

CO2 LASER for the treatment of vaginal symptoms of genitourinary syndrome of menopause

Gynecol Obstet Fertil Senol.

Jardin I, Canlorbe G, Mergui JL, Nikpayam M, Belghiti J, Uzan C, Azaïs H

doi: 10.1016/j.gofs.2018.09.001.

Menopause

The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review

Menopause.

Simon JA, Goldstein I, Kim NN, Davis SR, Kellogg-Spadt S, Lowenstein L, Pinkerton JV, Stuenkel CA, Traish AM, Archer DF, Bachmann G, Goldstein AT, Nappi RE, Vignozzi L

doi: 10.1097/

Urinary IncontinenceMenopause

Long-term effects of vaginal erbium laser in the treatment of genitourinary syndrome of menopause

Climacteric.

Gambacciani M, Levancini M, Russo E, Vacca L, Simoncini T, Cervigni M

doi: 10.1080/13697137.

Overactive Bladder

Vaginal Estrogen Therapy Is Associated with Increased Lactobacillus in the Urine of Post-Menopausal Women with Overactive Bladder Symptoms

Am J Obstet Gynecol.

Thomas-White K, Taege S, Limeira R, Brincat C, Joyce C, Hilt EE, Mac-Daniel L, Radek KA, Brubaker L, Mueller ER, Wolfe AJ

doi: 10.1016/j.ajog.2020.08.006.

Overactive Bladder

Beyond the bladder: poor sleep in women with overactive bladder syndrome

Am J Obstet Gynecol.

Savoie MB, Lee KA, Subak LL, Hernandez C, Schembri M, Fung CH, Grady D, Huang AJ

doi: 10.1016/j.ajog.2019.12.005.

Menopause

Efficacy of Erbium:YAG laser treatment compared to topical estriol treatment for symptoms of genitourinary syndrome of menopause

Lasers Surg Med.

Gaspar A, Brandi H, Gomez V, Luque D

doi: 10.1002/lsm.22569.

Overactive BladderUrinary Incontinence

Retrospective analysis in 46 women with vulvovaginal atrophy treated with ospemifene for 12 weeks: improvement in overactive bladder symptoms

Gynecol Endocrinol.

Schiavi MC, Zullo MA, Faiano P, D'Oria O, Prata G, Colagiovanni V, Giannini A, Di Tucci C, Perniola G, Di Donato V, Monti M, Muzii L, Benedetti Panici P

doi: 10.1080/

Related content

Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health

The impact of genitourinary syndrome of menopause on well-being, functioning, and quality of life in postmenopausal women

CO2 LASER for the treatment of vaginal symptoms of genitourinary syndrome of menopause

The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review

Long-term effects of vaginal erbium laser in the treatment of genitourinary syndrome of menopause

Vaginal Estrogen Therapy Is Associated with Increased Lactobacillus in the Urine of Post-Menopausal Women with Overactive Bladder Symptoms

Beyond the bladder: poor sleep in women with overactive bladder syndrome

Efficacy of Erbium:YAG laser treatment compared to topical estriol treatment for symptoms of genitourinary syndrome of menopause

Retrospective analysis in 46 women with vulvovaginal atrophy treated with ospemifene for 12 weeks: improvement in overactive bladder symptoms